Weight regain occurs in up to 37% of bariatric surgery patients, triggering return of diabetes, hypertension, and other obesity-related conditions while reducing quality of life. The analysis identifies GLP-1 receptor agonists liraglutide and semaglutide, dual incretin tirzepatide, and phentermine/topiramate combination as effective pharmaceutical interventions for post-surgical weight regain. This finding illuminates a critical gap in long-term obesity management that extends well beyond the operating room. The 37% regain rate underscores why bariatric surgery, despite being the most effective obesity treatment, requires lifelong medical management rather than representing a permanent cure. The emergence of GLP-1 medications as viable solutions offers hope for the estimated 200,000+ Americans who undergo bariatric procedures annually. These drugs work by mimicking hormones that regulate appetite and glucose metabolism, potentially addressing the underlying biological drives that contribute to weight regain. However, the lack of formal clinical guidelines for managing post-surgical weight regain represents a significant healthcare system failure. Patients invest considerable resources and health risks in bariatric procedures, yet receive inconsistent follow-up care. The research highlights an urgent need for standardized protocols combining frequent monitoring, mental health assessment, lifestyle reinforcement, and early pharmaceutical intervention to protect surgical investments and patient health outcomes.